Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus CAPOX as Neoadjuvant Therapy for Locally Advanced Colon Cancer
NCT06790212Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, randomised trial of ivonescimab in colon cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Major Pathologic Response Rate at 12 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06790212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790212.